January 1, 1993The Japanese Journal of PharmacologyOpen Access

KRI-1314: An Orally Effective Inhibitor of Human Renin

View Full Paper

Ask AI

Bookmark

Why the study?

Does KRI-1314 inhibit renin and lower blood pressure in preclinical models?

Population

In vitro models and in vivo models

Design

Preclinical

Follow-up

up to 7 hours

Authors

YEYasuo EtohKyushu University MMMizuo MiyazakiOsaka Medical and Pharmaceutical University HSHiroshi SaitohAxcelis Technologies (United States)

Discussion

Member takes

Implication

Supports further renin inhibitor development; hypothesis-generating for human hypertension trials.

Structured PICO

Does KRI-1314 inhibit renin and lower blood pressure in preclinical models?

Population

In vitro models (plasma renins from primates, dogs, rabbits, guinea pigs, rats; highly-purified human renin) and in vivo models (anesthetized and conscious sodium-depleted Japanese monkeys)

Intervention

KRI-1314 (intravenous 0.25 to 3 mg/kg and oral 10 and 30 mg/kg)

Outcome

Renin inhibition, blood pressure, plasma renin activity, and heart ratesurrogate

KRI-1314 is a potent, primate-selective, orally effective renin inhibitor that lowers blood pressure in preclinical models.

Cite This Study

Etoh et al. (1993) studied this question.

synapsesocial.com/papers/6a771fc3d3a6aa87c6bd951f https://doi.org/10.1254/jjp.63.109

View Full Paper

Ask AI

Bookmark

KRI-1314: An Orally Effective Inhibitor of Human Renin

Discussion

Member takes

Implication

Structured PICO

Cite This Study

KRI-1314: An Orally Effective Inhibitor of Human Renin

Discussion

Member takes

Implication

Structured PICO

Cite This Study

Also Consider

Also Consider